OncoMatch/Clinical Trials/NCT03739411
Hyperpolarized Imaging in Diagnosing Participants With Glioma
Is NCT03739411 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Chemotherapy for glioma.
Treatment: Chemotherapy — This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Lab requirements
Kidney function
creatinine < 1.5 mg/dL before starting therapy. This test must be performed within 60 days prior to Hyperpolarized Imaging scan.
Cardiac function
No NYHA Grade II or greater congestive heart failure. No history of myocardial infarction or unstable angina within 12 months prior to study enrollment.
adequate renal function (creatinine < 1.5 mg/dL)...must not have New York Heart Association (NYHA) Grade II or greater congestive heart failure...must not have a history of myocardial infarction or unstable angina within 12 months prior to study enrollment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify